enVVeno Medical (NVNO) Earnings Date & Reports

Key Takeaways

• enVVeno Medical reported a third-quarter 2026 net loss of $4.4 million, or $6.29 per share, compared with a net loss of $4.5 million, or $7.89 per share, in the same period last year.
• Total operating expenses came in at $4.5 million, down from $4.9 million a year earlier, even as the company prepared to launch its pivotal clinical study.
• The company ended the quarter with $18.5 million in cash and investments and reiterated that its resources are expected to fund operations into the fourth quarter of 2027.
• Quarterly cash burn was approximately $3 million, and management expects the burn rate to rise to between $4 million and $5 million per quarter in the first half of 2027 as patient enrollment accelerates.
• enVVeno remains a pre-revenue, clinical-stage company, making its regulatory and clinical milestones the primary drivers of shareholder value rather than top-line results.
• You can find more information about this ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages, which are worth exploring for a fuller picture.
• To discover automated trading strategies tailored to current market conditions, explore Trending AI Robots.

Earnings Context and Why It Matters

For a clinical-stage medical device company like enVVeno Medical, quarterly earnings are less about revenue and more about cash runway, expense discipline, and execution toward regulatory milestones. The company is developing the enVVe System, a first-in-class, non-surgical replacement venous valve for patients with severe deep chronic venous insufficiency (CVI), a condition affecting roughly 3 million people in the U.S. After receiving an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) earlier in 2026, enVVeno is now preparing to enroll its first patients in the TAVVE pivotal study. This quarter's report therefore matters because it shows whether the company has the capital and operational momentum to advance a potentially transformative therapy.

Reported Results

enVVeno Medical reported a net loss of $4.4 million for the third quarter ended September 30, 2026, translating to a loss of $6.29 per basic and diluted share. This compares with a net loss of $4.5 million, or $7.89 per share, in the third quarter of 2025. The company remains pre-revenue, so there were no product sales to report.

Total operating expenses were $4.5 million, down from $4.9 million in the prior-year quarter, reflecting disciplined cost management even as the company readied its TAVVE pivotal study for launch. Cash burn for the quarter was approximately $3 million. As of September 30, 2026, enVVeno held about $18.5 million in cash and investments, comprising $2.6 million in cash and cash equivalents and $15.9 million in short-term investments. Management reiterated that these resources are expected to fund operations into the fourth quarter of 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors tracking clinical-stage names like enVVeno Medical, tools such as the AI Screener can help streamline research and highlight potential opportunities across the healthcare sector.

Market Reaction and Investor Sentiment

Investor focus around enVVeno Medical's earnings has centered less on the income statement and more on the company's path toward enrolling patients in the TAVVE pivotal study. Management stated that clinical sites are being activated and that the company remains on schedule to enroll its first patient before the end of the year. This milestone, combined with an earlier analyst upgrade and a $30 price target from Ladenburg, has kept sentiment tied to execution risk rather than near-term profitability. Because enVVeno is pre-revenue, any setbacks in study timelines or unexpected capital needs could weigh heavily on the stock, while successful early enrollment milestones could reinforce confidence in the enVVe System's potential.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is the start of Part 1 of the TAVVE pivotal study, which is expected to enroll up to 10 patients whose 30-day safety data will be submitted to the FDA. Following that review, the company intends to move into Part 2, a randomized stage enrolling 220 patients — 165 receiving the enVVe System and 55 in a control arm.

Investors should monitor the pace of site activation and enrollment, as delays in either stage could extend timelines and pressure the company's cash position. Management anticipates the quarterly cash burn will rise to between $4 million and $5 million in the first half of 2027 as the study progresses.

Longer term, the company's objective is to submit a premarket approval (PMA) application to the FDA after completing 12-month follow-up on the randomized stage. Until then, key indicators to watch include operating expense trends, any additional financing activity, and the publication of early safety and efficacy data. As always, these developments carry meaningful clinical and regulatory risk, and there is no guarantee the enVVe System will receive FDA approval.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations